Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Dichelobacter nodosus serotype I; Dichelobacter nodosus serotype H; Dichelobacter nodosus serotype G; Dichelobacter nodosusserotype F ; Dichelobacter nodosus serotype E; Dichelobacter nodosus serotype D ; Dichelobacter nodosus serotype C ; Dichelobacter nodosus serotype B2; Dichelobacter nodosus serotype B1; Dichelobacter nodosus serotype A
Intervet Ireland Limited
QI04AB03
Dichelobacter nodosus serotype I; Dichelobacter nodosus serotype H; Dichelobacter nodosus serotype G; Dichelobacter nodosusserotype F ; Dichelobacter nodosus serotype E; Dichelobacter nodosus serotype D ; Dichelobacter nodosus serotype C ; Dichelobacter nodosus serotype B2; Dichelobacter nodosus serotype B1; Dichelobacter nodosus serotype A
.
Emulsion for injection
POM: Prescription Only Medicine as defined in relevant national legislation
Sheep
bacteroides
Immunological - Inactivated vaccine
Authorised
2004-02-20
Health Products Regulatory Authority 18 August 2021 CRN00C9YH Page 1 of 4 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Footvax Emulsion for Injection for Sheep 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1 ml dose contains: ACTIVE SUBSTANCES: _Dichelobacter nodosus _serotype A 10 μg pili equivalent to ≥400 potency units * _Dichelobacter nodosus _serotype B 1 10 μg pili equivalent to ≥400 potency units * _Dichelobacter nodosus _serotype B 2 10 μg pili equivalent to ≥400 potency units * _Dichelobacter nodosus _serotype C 10 μg pili equivalent to ≥400 potency units * _Dichelobacter nodosus _serotype D 10 μg pili equivalent to ≥400 potency units * _Dichelobacter nodosus _serotype E 10 μg pili equivalent to ≥400 potency units * _Dichelobacter nodosus _serotype F 10 μg pili equivalent to ≥400 potency units * _Dichelobacter nodosus _serotype G 10 μg pili equivalent to ≥400 potency units * _Dichelobacter nodosus _serotype H 10 μg pili equivalent to ≥400 potency units * _Dichelobacter nodosus _serotype I 5 x 10 8 cells/ml equivalent to ≥ 400 potency units * * based on the potency test ADJUVANTS: Light mineral oil 60.0 % v/v Mannide oleate 4.5 % v/v EXCIPIENTS: Preservative: thiomersal 0.015 % w/v For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Emulsion for injection. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Sheep from 4 weeks of age. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the active immunisation of sheep against footrot caused by _Dichelobacter nodosus_ for the purposes of reducing the risk of a clinical infection due to _Dichelobacter nodosus. _ Onset of immunity: 3 weeks after the primary vaccination course. Duration of immunity: 6 months. 4.3 CONTRAINDICATIONS None. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Vaccinate healthy animals only. Do not vaccinate sheep within 6 - 8 weeks of shearing. Health Products Regulatory Authority 18 August 2021 CRN00C9YH Page 2 of 4 Sheep destined for show or s Read the complete document